General Information of Drug (ID: DMWRVGE)

Drug Name
IC86621 Drug Info
Synonyms
DNA-PK Inhibitor III; 404009-40-1; IC86621; 1-(2-HYDROXY-4-MORPHOLINOPHENYL)ETHANONE; 1-(2-Hydroxy-4-morpholin-4-yl-phenyl)ethanone; CHEMBL1317546; Ethanone, 1-[2-hydroxy-4-(4-morpholinyl)phenyl]-; SCHEMBL600210; GTPL5960; CTK1D4579; CHEBI:95245; DTXSID40431950; MolPort-027-354-881; HMS3229C13; BCP08943; ZINC3817773; BDBM50398036; AR2783; 4512AH; IN1363; AKOS017560291; CCG-206744; NCGC00165807-01; AS-45440; IC 86621; RT-012395; 1-(2-hydroxy-4-morpholinophenyl)ethan-1-one; A-8048; 1-[2-hydroxy-4-(morpholin-4-yl)phenyl]ethan-1-one
Indication
Disease Entry ICD 11 Status REF
Discovery agent N.A. Investigative [1]
Cross-matching ID
PubChem CID
9859309
ChEBI ID
CHEBI:95245
CAS Number
CAS 404009-40-1
TTD Drug ID
DMWRVGE

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Clinical Trial Drug(s)
Investigative Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
M3814 DMK2L38 Locally advanced rectal cancer 2B92 Phase 1/2 [3]
AZD7648 DMD9Y5T Solid tumour/cancer 2A00-2F9Z Phase 1/2 [4]
M9831 DM59TI2 Solid tumour/cancer 2A00-2F9Z Phase 1 [3]
PP121 DMU8KTO Discovery agent N.A. Investigative [5]
LY-292223 DML36ZE Discovery agent N.A. Investigative [6]
Ethyl 1-[(1H-benzimidazol-2(3H)one-5-yl)sulfonyl]-1H-pyrrole-2-carboxylate DM3FH02 Discovery agent N.A. Investigative [7]
PIK-75 DM9BQTX Discovery agent N.A. Investigative [8]
KU-0060648 DMQWS6U Discovery agent N.A. Investigative [9]
Alpha-naphthoflavone DMELOIQ Discovery agent N.A. Investigative [10]
2-Morpholin-4-yl-pyrimido[2,1-a]isoquinolin-4-one DM79ZOV Discovery agent N.A. Investigative [10]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
DNA-dependent protein kinase catalytic (PRKDC) TTK3PY9 PRKDC_HUMAN Inhibitor [2]

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5960).
2 Modulation of DNA repair by pharmacological inhibitors of the PIKK protein kinase family. Bioorg Med Chem Lett. 2012 Sep 1;22(17):5352-9.
3 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
4 AZD7648 is a potent and selective DNA-PK inhibitor that enhances radiation, chemotherapy and olaparib activity. Nat Commun. 2019 Nov 7;10(1):5065.
5 Targeted polypharmacology: discovery of dual inhibitors of tyrosine and phosphoinositide kinases. Nat Chem Biol. 2008 Nov;4(11):691-9.
6 Identification of a highly potent and selective DNA-dependent protein kinase (DNA-PK) inhibitor (NU7441) by screening of chromenone libraries. Bioorg Med Chem Lett. 2004 Dec 20;14(24):6083-7.
7 Discovery of potent chromen-4-one inhibitors of the DNA-dependent protein kinase (DNA-PK) using a small-molecule library approach. J Med Chem. 2005 Dec 1;48(24):7829-46.
8 A pharmacological map of the PI3-K family defines a role for p110alpha in insulin signaling. Cell. 2006 May 19;125(4):733-47.
9 1-substituted (Dibenzo[b,d]thiophen-4-yl)-2-morpholino-4H-chromen-4-ones endowed with dual DNA-PK/PI3-K inhibitory activity. J Med Chem. 2013 Aug 22;56(16):6386-401.
10 Selective benzopyranone and pyrimido[2,1-a]isoquinolin-4-one inhibitors of DNA-dependent protein kinase: synthesis, structure-activity studies, and... J Med Chem. 2005 Jan 27;48(2):569-85.